Oruka Therapeutics Inc (ORKA)

Currency in USD
63.665
+1.085(+1.73%)
Real-time Data·
ORKA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
60.97764.000
52 wk Range
8.91091.000
Key Statistics
Prev. Close
62.58
Open
61.4
Day's Range
60.977-64
52 wk Range
8.91-91
Volume
569.79K
Average Volume (3m)
1.12M
1-Year Change
484.3137%
Book Value / Share
9.69
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ORKA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
142.167
Upside
+123.30%
Members' Sentiments
Bearish
Bullish
ProTips
Stock has taken a big hit over the last week

Oruka Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

13 Buy
0 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 142.167
(+123.30% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
H.C. Wainwright
Buy120.00+90.63%75.00MaintainApr 29, 2026
UBS
Buy100.00+58.86%75.00MaintainApr 28, 2026
Clear Street
Buy131.00+108.10%71.00MaintainApr 27, 2026
Guggenheim
Buy200.00+217.71%125.00MaintainApr 27, 2026
Barclays
Buy160.00+154.17%78.00MaintainApr 27, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-0.45 / -0.72
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ORKA Income Statement

Compare ORKA to Peers and Sector

Metrics to compare
ORKA
Peers
Sector
Relationship
P/E Ratio
−44.4x−3.2x−0.5x
PEG Ratio
−0.79−0.050.00
Price/Book
8.0x3.7x2.6x
Price / LTM Sales
-197.2x3.3x
Upside (Analyst Target)
126.1%96.4%47.7%
Fair Value Upside
Unlock1.6%6.6%Unlock

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
7.84M15.62%490.64M
Other Institutional Investors
20.40M40.64%1.28B
Public Companies & Retail Investors
21.96M43.74%1.37B
Total
50.2M100.00%3.14B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
FMR LLC14.47%7,261,384454,417
VR Management, LLC8.26%4,148,428259,609

People Also Watch

97.305
AXTI
+1.36%
78.76
MXL
+2.05%
964.85
LITE
+1.57%
16.5900
LWLG
+1.97%
53.99
VIAV
-2.42%

FAQ

What Is the Oruka Therapeutics (ORKA) Stock Price Today?

The Oruka Therapeutics stock price today is 63.665 USD.

What Stock Exchange Does Oruka Therapeutics Trade On?

Oruka Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Oruka Therapeutics?

The stock symbol for Oruka Therapeutics is "ORKA."

What Is the Oruka Therapeutics Market Cap?

As of today, Oruka Therapeutics market cap is 3.770B USD.

What Is Oruka Therapeutics's Earnings Per Share (TTM)?

The Oruka Therapeutics EPS (TTM) is -1.848.

From a Technical Analysis Perspective, Is ORKA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Oruka Therapeutics Stock Split?

Oruka Therapeutics has split 6 times.

How Many Employees Does Oruka Therapeutics Have?

Oruka Therapeutics has 68 employees.

What is the current trading status of Oruka Therapeutics (ORKA)?

As of May 04, 2026, Oruka Therapeutics (ORKA) is trading at a price of 63.665 USD, with a previous close of 62.580 USD. The stock has fluctuated within a day range of 60.977 USD to 64.000 USD, while its 52-week range spans from 8.910 USD to 91.000 USD.

What Is Oruka Therapeutics (ORKA) Price Target According to Analysts?

The average 12-month price target for Oruka Therapeutics is 142.167 USD, with a high estimate of 200 USD and a low estimate of 100 USD. 13 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +123.30% Upside potential.

What Is the ORKA Premarket Price?

ORKA's last pre-market stock price is 61.250 USD. The pre-market share volume is 11,320.000, and the stock has decreased by -1.330, or -2.130%.

What Is the ORKA After Hours Price?

ORKA's last after hours stock price is 60.710 USD, the stock has decreased by -1.870, or -2.990%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.